• Ganoderma Polysaccharide Boosts mRNA-LNP Efficacy

  2026-08-14

  A 2026 Pharmaceutics study identifies Ganoderma lucidum polysaccharide as an adjuvant that can improve mRNA-LNP protein expression while reducing carrier-associated oxidative stress. The work connects enhanced expression with glutathione and superoxide dismutase recovery, malondialdehyde reduction, and engagement of the Nrf2 pathway, offering a rationale for redox-aware delivery design.

• CCT007093: Practical PPM1D Assay Guidance

  2026-08-14

  Learn how CCT007093 (SKU B3274) can support mechanistic viability, proliferation, and cytotoxicity studies involving PPM1D and P38 MAPK signaling. This scenario-based guide covers assay design, solvent handling, pathway validation, interpretation, and practical product selection.

• PBS (Phosphate-Buffered Saline): Practical Guide

  2026-08-13

  PBS (Phosphate-Buffered Saline), SKU K2818, provides a sterile, isotonic solution for cell washing, reagent dilution, and selected in vitro assay workflows. It is intended for controlled scientific research only and should not be used for diagnostic, medical, or in vivo applications.

• WRN–MMR Synthetic Lethality in Colon Cancer

  2026-08-13

  The reference study explains why mismatch repair-deficient, microsatellite-unstable colorectal cancer cells depend on Werner helicase: WRN loss activates a p53/PUMA apoptotic program. Genetic and pharmacological experiments, including xenograft models, identify p53 and PUMA status as important determinants of response and support WRN as a preclinical target in p53-wild-type MSI tumors.

• Brain-to-Spinal Control of Opioid Hypersensitivity

  2026-08-12

  A 2024 Neuron study identifies a lateral parabrachial–hypothalamic–spinal pathway that controls morphine-induced mechanical hypersensitivity and analgesic tolerance in mice. Its circuit-level findings distinguish mechanical pain consequences from better-established thermal mechanisms and provide a framework for combining behavioral, anatomical, and receptor-focused experiments.

• Tiamulin (Thiamutilin): From Ribosome to Translation

  2026-08-12

  Tiamulin (Thiamutilin) is more than a veterinary pleuromutilin antibiotic: its ribosomal binding architecture, resistance liabilities, exposure benchmarks, and investigational anti-inflammatory activity create a practical framework for translational research.

• HMGB1 for Early Diabetic Nephropathy Monitoring

  2026-08-11

  A 2024 iScience study used serum quantitative proteomics, Mfuzz clustering, and WGCNA to identify proteins associated with diabetic nephropathy progression. HMGB1 was prioritized as a candidate early monitoring biomarker because its serum pattern tracked renal function changes and was reproduced under high-glucose conditions in cellular and animal models.

• Mild UPRER Activation and Cadmium Resistance in C. elegans

  2026-08-11

  The reference study shows that moderate activation of the endoplasmic reticulum unfolded protein response protects Caenorhabditis elegans from cadmium, whereas excessive activation is inhibitory. Genetic evidence identifies the IRE-1/XBP-1 branch and protein-homeostasis maintenance as central to this resistance phenotype, providing a mechanistic framework for studying environmental toxicant adaptation.

• Dabigatran Etexilate: Direct Thrombin Inhibition

  2026-08-10

  The reference review presents dabigatran etexilate as the first marketed oral direct thrombin inhibitor and explains how its prodrug design addressed important limitations of warfarin and parenteral anticoagulants. Its synthesis of pharmacology, pharmacokinetics, clinical efficacy, tolerability, and renal considerations remains useful for interpreting anticoagulant for atrial fibrillation research and translational coagulation studies.

• Esflurbiprofen and SERT–nNOS: A Fast-Acting Pathway

  2026-08-09

  The reference study identifies esflurbiprofen as a candidate fast-onset antidepressant that disrupts the SERT–nNOS complex in the dorsal raphe nucleus. By combining mBRET-based interaction screening, stress models, brain exposure studies, and rs-fMRI, the authors connect molecular complex disruption with altered serotonergic feedback, behavior, and emotion-related network connectivity.

• FLCN Mutations and mRNA Rescue in BHD Syndrome

  2026-08-08

  A 2026 study identified the novel FLCN nonsense variant p.Q44* and provided segregation and functional evidence that supports reclassifying p.W376R as pathogenic in two Chinese Birt-Hogg-Dubé families. In HEK293T cells, synthetic FLCN mRNA restored folliculin expression and reduced abnormal mTORC1 signaling, offering an early in vitro rationale for mRNA-based protein replacement while remaining far from clinical validation.

• Resiquimod: Designing Better Ablation Assays

  2026-08-07

  Resiquimod (R-848) is a dual TLR7/8 agonist that can turn tumor-ablation studies into mechanistically resolved chemo-immunotherapy experiments. This guide focuses on assay architecture, controls, compound handling, and interpretation rather than repeating broad hydrogel design concepts.

• Doxycycline in Tumor Microenvironment Modulation and MMP-2 R

  2026-08-07

  Explore the multifaceted role of Doxycycline as a tetracycline antibiotic in modulating the tumor microenvironment via metalloproteinase inhibition. This article uniquely connects Doxycycline’s chemical properties and research-grade handling to breakthrough findings in cancer therapy and drug delivery.

• Dabigatran etexilate: Direct Thrombin Inhibition in Coagulat

  2026-08-06

  Dabigatran etexilate, a potent oral direct thrombin inhibitor, streamlines both in vitro and in vivo anticoagulant research by enabling precise, reproducible modulation of the coagulation cascade. Its rapid onset and predictable effects make it the gold standard for studies targeting stroke prevention and atrial fibrillation models.

• Dabigatran Etexilate: Clinical Evidence for Oral Thrombin In

  2026-08-06

  This review highlights the clinical innovation and mechanistic clarity provided by dabigatran etexilate as the first oral direct thrombin inhibitor for stroke and VTE prevention. The reference study demonstrates its rapid, predictable anticoagulant profile and significant advantages over traditional anticoagulants, informing both translational research and therapeutic strategies.

15539 records 1/1036 page Next 12345 下5页 Last page